| |
[SORT BY TITLE] [SORT BY DATE] [SORT BY AUTHOR]
FDA Reform
- Why Does FDA Keep Drugmakers From Informing Doctors? Investor's Business Daily, James R. Copland, Paul Howard, 01-09-13
- Paul Howard interviews Jeffrey Kasher about Lilly's involvement in TransCelerate BioPharma, an industry-wide collaboration that is aimed at developing shared research solutions to accelerate the deliv Podcast: Interview, Paul Howard, October 8, 2012
- Paul Howard interviews Josh Bloom, director, chemical and pharmaceutical sciences, American Council on Health and Science, about his MedicalProgressToday.com article, "Qsymia is Not Fen-Phen." Podcast: Interview, Paul Howard, July 25, 2012
- FDA Approvals Are a Matter of Life and Death Wall Street Journal, Dr. Andrew von Eschenbach, 06-17-12
- Paul Howard and Avik Roy discuss findings from the American Society of Clinical Oncology conference and what is driving cancer innovation forward. Podcast: Interview, Avik Roy, Paul Howard, June 7, 2012
- Improving the FDA Washington Examiner, Paul Howard, 05-24-12
- How the FDA Stifles New Cures, Part I & II Forbes.com, Avik Roy, 04-25-12
- Market-Oriented Medicare Advantage is Especially Popular in Big Swing States National Review Online, Avik Roy, 04-24-12
- Sens. Richard Burr and Tom Coburn Introduce a New Plan to Reform the FDA Forbes.com, Avik Roy, 04-18-12
- Toward a 21st-Century FDA Wall Street Journal, Dr. Andrew von Eschenbach, 04-15-12
- Paul Howard and Alex Tabarrok discuss the recent surge in drug shortages and what the U.S. can do to bring more drugs to market Podcast: Interview, Paul Howard, April 4, 2012
- Unshackle the FDA From Rules That Kill Innovation Forbes.com, Richard A. Epstein, 03-15-12
- Market Better Than FDA To Address Drug Shortages Washington Examiner, Paul Howard, 03-01-12
- Innovation, Not Spending Cuts, Improves Health Care Investor's Business Daily, Paul Howard, 01-04-12
- Expensive Innovation Is Only Path To Cheap Lipitor Washington Times, Paul Howard, 12-22-11
- The End of the Age of Lipitor? You'd Better Hope Not. Medical Progress Today, Paul Howard, 11-30-11
- Gates Invests Time, Cash Into Drug Research Washington Examiner, Paul Howard, 11-25-11
- How To Liberate New Frontier Of Modern American Medicine Investor's Business Daily, Douglas Holtz-Eakin, 11-09-11
- Renewing User-Fee Program Will Boost Innovation, FDA Performance Washington Examiner, Paul Howard, 11-03-11
- Former Obama Adviser Warns of the Perils of Price Controls National Review Online, Paul Howard, 08-17-11
- Don't Forget About the FDA National Review Online, Paul Howard, 08-12-11
- Paul Howard interviews Marc M. Boutin, about PEDUFA and why the FDA needs to re-evaluate the way it approves drugs and medical devices. Podcast: Interview, Paul Howard, July 21, 2011
- High-Priced Cancer Drugs: Are They Worth It? National Review Online, Paul Howard, 07-08-11
- Supreme Court Drug Decisions Are Blows For Common Sense Washington Examiner, James R. Copland, 06-30-11
- Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research Project FDA Report, Tomas J. Philipson, Eric Sun, June 2011
- Why We Need an FDA 2.0 National Review Online, Paul Howard, 06-24-11
- Cancer Revolution Is Possible With More Flexible FDA Washington Examiner, Paul Howard, 06-09-11
- About the FDA's New Calorie Count Regulations The Weekly Standard, David Gratzer, 04-06-11
- The Real Problem With Withdrawing Avastin Health Affairs, Paul Howard, 01-19-11
- The Right Way to Stop Superbugs New York Post, David Gratzer, 11-12-10
- Causing More Harm than Good: Conflict-of-Interest Rules Thwart Medical Progress Forbes.com, Richard A. Epstein, 10-26-10
- Richard Epstein explains why the FDA should not fear conflicts-of-interest and gives his solutions for the dilemma. Podcast: Interview, Paul Howard, Richard A. Epstein, October 19, 2010
- The Way Forward On Health Care, And No, It's Not Obamacare FoxNews.com, Douglas Holtz-Eakin, Paul Howard, 09-29-10
- CBO: Cutting the Fat Will Cut Costs Blog Post, David Gratzer, 09-15-10
- Making the FDA More Patient-Friendly Blog Post, David Gratzer, 06-16-10
- Quantifying High Cost Of Caution May Speed Drug Approval Process Investor's Business Daily, Tomas J. Philipson, Eric Sun, 06-14-10
- Cost of Caution: The Impact on Patients of Delayed Drug Approvals Project FDA Report, Tomas J. Philipson, Eric Sun, June 2010
- 'Caution Syndrome' Infects The FDA Forbes.com, David Gratzer, 05-21-09
- In the Wake of Wyeth v. Levine: Making the Case for FDA Preemption and Administrative Compensation Project FDA Report, Paul Howard, James R. Copland, March 2009
- Do You Know Where Your Food Comes From? RealClearMarkets, Diana Furchtgott-Roth, 02-19-09
- The right prescription for drug safety Washington Examiner, Marie Gryphon, Paul Howard, 12-04-08
- The Cure: How Capitalism Can Save American Health Care Book, David Gratzer, October 2006
- The Bureaucratization of Safety and Effectiveness Medical Progress Today, Dr. Benjamin Zycher, 07-07-06
- Prescription for Progress: The Critical Path To Drug Development Medical Progress Report, Robert M. Goldberg, June 2006
- Medical Progress and the FDA: Our Future in the Balance MI Conference Series, June 2002
|
|
|
